+1-888-308-5802     
News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Datadog launches partner program to support channel partners in ANZ

Published Date: 2020-01-18         Author: Pankaj Singh

Datadog, the global monitoring and cloud-scale analytics platform for developers, IT teams, and business users, recently announced the launch of a new partner program, expanding its support for channel partners in Australia & New Zealand. The Datadog Partner Network will offer a structured platf... Read More

Banco Sabadell and TSB ink a cloud services contract with IBM

Published Date: 2020-01-17         Author: Pankaj Singh

Banco Sabadell, a Spain-based banking group, has inked a ten-year agreement with IBM to advance its hybrid cloud strategy. Sources cite that this deal is intended to streamline Sabadell’s dispersed technological infrastructure to move and manage data, services, and workflows across multip... Read More

NI partners with Braemac to broaden its Australia & New Zealand market

Published Date: 2020-01-16         Author: Pankaj Singh

NI, a Texas based provider of software defined platform that helps accelerate productivity, innovation and discovery, has reportedly announced that Braemac would now be the authorized distributor of NI products in Australia and New Zealand. Braemac, an authorized distributor of NI, would now wide... Read More

© 2020 Fractovia. All Rights Reserved